Finkelstein Thompson LLP is investigating potential shareholder claims involving AtriCure, Inc. (“Atricure” or the “Company”) (NasdaqGM: ATRC).
On November 3, 2008, AtriCure shares plunged 39% after the Company revealed that its marketing practices are being investigated by the Department of Justice (“DOJ”). According to an AtriCure press release, the DOJ wrote a letter to AtriCure stating that it was investigating the Company’s alleged marketing of the off-label use of the Company’s surgical tissue-ablation system to treat atrial fibrillation. The letter also stated that the DOJ is investigating whether AtriCure directed hospitals to bill for surgical-ablation procedures using incorrect billing codes. On this news, the Company’s stock fell nearly 40% to close at $3.89 per share on unusually high trading volume.
If you are an AtriCure shareholder and wish to discuss your rights and interests as an investor, please contact our Washington, D.C. office toll-free at (877) 337-1050 or by email at contact@finkelsteinthompson.com.
Attorney Advertisement. Prior results do not guarantee similar outcomes. Please see legal disclaimer.
Post a Comment